Vascular smooth muscle (VSM) proliferation and migration are key components in vessel remodeling. Cyclic nucleotide signaling is protective and has long-served as a therapeutic target against undesired VSM growth. The present work analyzed the effects of the soluble guanylate cyclase (sGC) stimulator 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine [BAY 41-2272 (BAY)] on VSM growth, and we hypothesize that BAY has the capacity to reduce proliferation and migration via cyclic nucleotide-driven kinase signaling. Perivascular BAY postballoon injury reduced neointimal growth by ϳ40% compared with vehicle controls after 2 weeks. In VSM cells, BAY (10 M) reduced proliferation by ϳ40% after 72 h and migration by ϳ40% after 6 h and ϳ60% after 18 h without deleterious effects on cell viability. cGMP content peaked (248ϫ) 20 min after BAY treatment and remained elevated (140ϫ) through 60 min; however, BAY did not affect cAMP levels compared with controls.
Introduction
Proliferation and migration of vascular smooth muscle (VSM) cells (VSMCs) are key components during the evolution of an atherosclerotic plaque and in the vessel response to injury or intervention. Investigations have attempted to reduce pathologic vessel growth through various interventions including targeted gene delivery (Tulis et al., 2001) , the use of drug-coated stents, and localized application of pharmacological agents to the arterial wall (Tulis et al., 2002) . Despite advances in genetic and pharmacother-apy, aberrant VSM growth remains a key contributing factor in vascular pathogenesis, but full characterization of the precise signals involved remains elusive.
Cyclic nucleotide signaling affects numerous homeostatic and pathophysiologic functions in VSM. Carbon monoxide is liberated by the catalytic action of heme oxygenase (HO) on heme, which releases iron and produces the antioxidants bilirubin and biliverdin. Nitric-oxide synthase (NOS) catalyzes conversion of L-arginine to L-citrulline, liberating NO. Binding of CO or NO causes conformational changes in sGC that determines their unique abilities to stimulate the enzyme. Binding of NO causes a 400-fold increase in enzyme activity, whereas CO is able to stimulate the enzyme 4-to 6-fold under controlled conditions (Friebe et al., 1996) . Although a relatively poor stimulator compared with NO, CO remains a potent physiological regulator of cGMP-mediated effects in VSM (Liu et al., 2009) .
Advances in synthetic, NO-independent sGC stimulators and activators have further established the validity of the CO system to modulate VSM biology. We and others have shown that the sGC stimulator YC-1 [3-(5Ј-hydroxymethyl-2Ј-furyl)-1-benzyl indazole] exerts antigrowth effects in VSM under in vivo and in vitro conditions (Tulis et al., 2002; Wu et al., 2004) , lending support for CO-directed, cGMP-driven growth suppression. We have investigated 3-(4-amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b] pyridine [BAY 41-2272 (BAY) ], a second-generation YC-1 analog, and found that in rat A7R5 VSMCs BAY stimulates cAMP and cGMP and increases site-specific phosphorylation of vasodilator-stimulated phosphoprotein (VASP) in a manner suggestive of cAMPdependent protein kinase (PKA) signaling . In this study BAY was also found to exert cytostasis through reduced cyclin-dependent kinase (Cdk) and elevated Cdk inhibitor expression. In addition, BAY has been reported to possess antihypertensive and antiplatelet effects (Boerrigter et al., 2003) , making it an attractive agent for further study to target cardiovascular disorders.
cAMP and cGMP activate PKA and PKG, respectively, leading to phosphorylation of key regulatory proteins, including VASP, which plays important roles in controlling cytoskeleton dynamics and cell migration (Reinhard et al., 2001) . In platelets, VSMCs, and vascular endothelial cells VASP is associated with actin filaments, focal adhesions, and cell-cell contacts. VASP can be phosphorylated on three sites: serine 157 (a PKA-preferred site), serine 239 (a PKG-preferred site), and threonine 278 (an AMP kinase-activated site) (Butt et al., 1994; Reinhard et al., 2001) . VASPSer 157 has also been shown to be phosphorylated in response to growth factors activated by protein kinase C . Although VASP phosphorylation is often used as a biochemical marker for activation of PKG and PKA, it possesses important cellular and molecular functions that have yet to be fully elucidated in VSM.
In VSMCs, cGMP-driven PKG has been shown to modulate apoptosis, proliferation, (Chiche et al., 1998) , migration (Boerth et al., 1997) , and extracellular matrix protein expression (Reinhard et al., 2001) , suggesting involvement in normal cellular homeostasis. In the current study, we investigated the influence of BAY-induced cGMP signaling in VSM growth in vivo and in vitro, using VASPSer 157 and VASPSer 239 as readouts for respective PKA or PKG and as functional mediators of growth. Our a priori hypothesis is that BAY serves to reduce VSM growth through reduction in proliferation and migration and via mechanisms involving cyclic nucleotide-driven kinases. Results show that BAY reduces proliferation and migration of primary VSM through the actions of cGMP/PKA and cGMP/ PKG/VASPSer 239 , respectively. These findings provide the first evidence for BAY in limiting VSM growth and that cGMP has the capacity to influence distinct downstream targets (PKA, PKG, phosphoVASP), resulting in discrete regulation of VSM growth.
Materials and Methods
This study abided by the guidelines of the Institutional Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) .
Rat Carotid Artery Balloon Injury Model. The in vivo arterial response to injury was studied using the highly characterized rat carotid artery (CA) model of balloon injury (Tulis, 2007a) . In brief, male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 450 to 550 g were anesthetized with a combination anesthetic (ketamine, 90 mg/ml; xylazine, 10 mg/ml; 1 ml/kg i.p.) and provided buprenorphine (Buprenex; 0.5 ml/kg s.c.) supplied by the Department of Comparative Medicine, Brody School of Medicine, East Carolina University, Greenville, NC. The left common CA and external carotid branch were exposed, and a Fogarty 2F embolectomy catheter (Baxter Healthcare Corp., Irvine, CA) was introduced into the external carotid branch through an arteriotomy and advanced uninflated to the aortic arch. The balloon was inflated to 2 atm (0.02 ml) and withdrawn three times with rotation. The catheter was removed and the external carotid artery was ligated. Vessel patency and CA blood flow were verified, overlying tissue was sutured, and the skin was closed with rodent wound clips. After full recovery from anesthesia, animals were returned to the animal care facility and provided standard rat chow and water ad libitum.
BAY 41-2272. Following established protocols for topical application of pharmacologic agents to carotid vasculature (Tulis, 2007a) , BAY 41-2272 (1 mg; Enzo Life Sciences, Inc., Farmingdale, NY) was dissolved in 50 l of DMSO (Calbiochem, San Diego, CA) and mixed into 200 l of a 25% solution of a copolymer gel (Pluronic F-127; BASF Corporation, Mount Olive, NJ). Immediately after balloon injury and closure of the external carotid arteriotomy, the BAYPluronic F-127 gel mixture was administered topically and circumferentially on the exposed adventitia of the CA section. Control animals were treated with 200 l of gel containing 50 l of DMSO. The right CA served as the unmanipulated untreated control.
Tissue Processing and Staining. Following protocols for histology of rat vascular tissues (Tulis, 2007b) , 2 weeks after injury rats were sacrificed by an anesthetic overdose followed by pneumothorax and exsanguination. The thoracic artery was clamped and normal saline was perfused transcardially followed by 10% buffered formalin in PBS. Carotid arteries were harvested, postfixed, and processed in graded alcohols and aliphatic xylene substitute (VWR, West Chester, PA) and embedded in paraffin. For elastin staining, slides were deparaffinized, rehydrated, and stained with elastic staining solution containing alcoholic hematoxylin, ferric chloride, and Weigert's iodine. Slides were differentiated in ferric chloride and Van Gieson-counterstained. Images were captured microscopically (Leica DM5000B; Leica, Wetzlar, Germany) and analyzed using Image Pro Plus 6.3 software (Media Cybernetics, Inc., Bethesda, MD).
Rat Primary VSMC Cultures. VSMCs were isolated from the thoracic aorta of male Sprague-Dawley rats (100 -125 g) by collagenase and elastase digestion (Tulis et al., 2002; Liu et al., 2009 ). Cells were cultured serially (passages 1-6) in Dulbecco's minimum Eagle's media (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, sodium pyruvate, 5 mM HEPES and Primocin (100 mg/l) in the presence of 95% air/5% CO 2 . jpet.aspetjournals.org cGMP and cAMP Assays. Primary VSMCs were grown in 24-well plates (60,000 cells/well), and cyclic nucleotide enzyme-linked immunosorbent assay-based assays (Sigma, St. Louis, MO) were performed according to the manufacturer's guidelines. In brief, after pretreatment with IBMX (1 mM; 15 min), cells were incubated in the presence of BAY for specific times, after which cyclic nucleotides were extracted in 0.1 M HCl and their contents were estimated. Protein was determined using the BCA protein assay (Thermo Fisher Scientific, Waltham, MA), and cyclic nucleotide content was normalized to total protein within each sample.
VSMC Proliferation. VSMCs were seeded in 48-well plates (25,000 cells/well), and after adherence they were quiesced overnight in 0.2% FBS. Cells were treated with either vehicle (DMSO in DMEM) or BAY (0.001, 0.1, or 10 M in DMSO/DMEM) for 72 h. For the kinase inhibitor studies, cells were incubated in the presence or absence of BAY (10 M) along with the PKG inhibitor YGRK-KRRQRRRPPLRKKKKKH peptide (DT-2) (10 M in DMSO/DMEM) (Dey et al., 2005) or the PKA inhibitor (PKI) (1 M in DMSO/DMEM) (Schlegel and Waschke, 2009 ) for 72 h. Cells in each well were then trypsinized individually (0.25% trypsin, 5 min, 37°C), and cell counts were estimated using hemocytometry.
Cell Cycle Analysis. Flow cytometry was performed as routine. In brief, VSMCs were seeded in 48-well plates (30,000 cells/well), and after adherence they were quiesced overnight in 0.2% FBS containing DMEM. Cells were then treated with vehicle or BAY (10 M), and after 24 h cells were trypsinized, fixed in cold ethanol, stained with propidium iodide, and subjected to flow cytometry (Accuri C6; Accuri Cytometers Inc., Ann Arbor, MI).
Neutral Red Uptake. To evaluate cellular viability and cytotoxicity of BAY, the neutral red uptake assay was performed with minor modifications. In brief, VSMCs were seeded in 96-well plates (18,000 cells/well) and grown for 24 h. Cells were then incubated in the presence of vehicle or BAY (10 M) for 18 h, after which treatments were replaced with neutral red solution in complete media and incubated at 37°C for 3 h. Cells were washed with warm PBS and neutral red was extracted using 200 l/well acetic ethanol solution. Extracts (150 l) from each well were transferred to new 96-well plates and read at 540 nm.
Migration Assays. Two standardized assays were used to estimate cell migration. Nonspecific migration was assessed using an in vitro scrape injury model (Yang et al., 2006) . In brief, VSMCs were seeded in 24-well plates (75,000 cells/well) and grown to confluence. A cell scraper was fabricated to approximately 1-mm width. Cells were pretreated with respective BAY concentrations (1 nM-10 M) for 20 min. A portion of the cell layer was then denuded via scraping, after which cells were washed with PBS and incubated in vehicle/ BAY treatments in complete media. The scraped regions were photographed immediately after injury (time 0) and after 18, 24, and 42 h under an inverted microscope (Leica DMI4000B). Using a micrometer scale the images were calibrated, and the distances between the edges of the scrape were measured (between six and eight measurements per well). The extent of VSMC migration in the presence of vehicle and BAY at 18, 24, or 42 h was calculated relative to time 0, and the scrape injury distance for each respective well was calculated. The BAY treatments were then normalized to vehicle controls and percentage of regrowth was determined.
A transwell chemotactic migration assay was also performed (Yang et al., 2006) . In brief, VSMCs (9000 -18,000) were seeded on membrane inserts (Costar Transwell; Corning Life Sciences, Lowell, MA; 8.0-m pores; 6.4-mm diameter) in complete DMEM, with the bottom part of the well containing only DMEM. After adherence, media in the top portion of the insert were replaced with vehicle or BAY with/without the PKA and PKG inhibitors PKI and DT-2, respectively, in DMSO/DMEM. The inhibitors were added 15 min before BAY treatment. The chemoattractant PDGF (2 ng/ml) was added to the bottom portions of the wells after 15 min of vehicle/drug treatment. After 6 h the top portion of the insert was cleaned with a cotton Q-tip and the media in the bottom part of the well were replaced with 4% buffered formalin solution to fix the cells for 20 min. The migrated cells on the bottom part of the inserts were stained with hematoxylin solution. Within each insert, six fields were counted under light microscopy. Each treatment set was normalized to its respective vehicle control from the same plate and presented as percentage of migration.
Western Blotting. Traditional Western blotting was performed on whole-cell lysates ) with slight modifications. After treatment, cells were collected, homogenized, sonicated, and boiled, and SDS-polyacrylamide gel electrophoresis was performed using 20 g of protein samples. The separated blots were transferred to nitrocellulose membrane, blocked, and incubated with antibodies directed against VASP, pVASPSer 157 , pVASPSer 239 (Cell Signaling Technology, Danvers, MA), PKA, PKG (Abcam Inc., Cambridge, MA), and pPKASer 338 (Biosource International, Camarillo, CA), all at 1:1000 dilution and incubated overnight at 4°C. After washes the membranes were incubated in anti-rabbit horseradish peroxidase-conjugated secondary antibodies (1:1000) for 1 h at room temperature. Blots were washed and incubated in Pierce enhanced chemiluminescence reagents (Thermo Fisher Scientific) and exposed to photographic film. Densitometry was performed using ImageJ 1.42q software (National Institutes of Health, Bethesda, MD). The blots were stripped of the antibodies at 50°C for 30 min using a stripping solution containing 10% SDS and 100 mM 2-mercaptoethanol in 62.5 mM Tris buffer, pH 6.8, before reprobing for complementary proteins.
In-Cell Western Assays. The In-Cell Western (ICW) method was used on intact adherent cells to study phosphorylation events stimulated by BAY alone or in the presence of PKA and PKG inhibitors (Chen et al., 2005) . Primary VSMCs were seeded in black 96-well, flat-bottom plates (22,000 cells/well) and, after attachment, treated with BAY (10 M) with or without the PKA and PKG inhibitors PKI or DT-2 (each at 5 and 10 M) using appropriate vehicle controls for a total incubation time of 60 min. Reactions were stopped by replacing media with 4% phosphate-buffered formalin. Fixed cells were permeabilized with 0.1% Triton X-100, blocked, and incubated with rabbit antibodies against total VASP or the phosphorylated forms of VASP at serines 157 or 239 (Cell Signaling Technology) along with mouse ␣-tubulin (Sigma) as the housekeeping control at 1:500 dilutions overnight at 4°C. The cells were washed with PBS-Tween and incubated with anti-rabbit IR 800 and anti-mouse IR 680 (Rockland Immunochemicals, Gilbertsville, PA) secondary antibodies for 1 h. The proteins were quantified by fluorescence (LI-COR Odyssey; LI-COR Biosciences, Lincoln, NE) and normalized with respect to ␣-tubulin within each well.
Statistical Analyses. Data were analyzed using Excel 2007 (Microsoft, Redmond, WA) and Sigma Plot 11 (SPSS, Inc., Chicago, IL). Comparisons between treatment groups were made using one-way analysis of variance (ANOVA) and a multiple comparison NewmanKeuls post hoc test or Student's t test as indicated. All data are presented mean Ϯ S.E.M. A p value of Ͻ0.05 is considered statistically significant for all comparisons.
Results
Rat Carotid Artery Balloon Injury Model. Perivascular treatment of rat carotid arteries with BAY immediately after balloon injury significantly reduced neointimal (NI) growth compared with vehicle-treated arteries 2 weeks after injury. Representative photomicrographs (400ϫ) of ballooninjured, perfusion-fixed left CA cross-sections of vehicle-and BAY-treated vessels are shown in Fig. 1, A and B, respectively. Morphometric analyses show that the NI area was reduced ϳ40% (p Ͻ 0.01) (Fig. 1C ) and the NI/medial wall (MW) area ratio was reduced ϳ50% (p Ͻ 0.05) in BAYtreated vessels compared with vehicle controls (Fig. 1D ). Significant differences in arterial MW areas were not de- 2 ) injured arteries 2 weeks postinjury. Likewise, significant differences were not detected in adventitial areas between BAY-treated (0.179 Ϯ 0.018 mm 2 ) and vehicle-treated (0.2079 Ϯ 0.043 mm 2 ) injured arteries after 2 weeks. Lengths of the external and internal elastic lamina were also not different between BAYand vehicle-treated injured vessels at this time point (external elastic lamina, 2.68 Ϯ 0.039 versus 2.61 Ϯ 0.08; internal elastic lamina, 2.40 Ϯ 0.03 versus 2.32 Ϯ 0.07, respectively).
Rat Primary VSMC Culture Studies. Using hemocytometry, BAY (10 M) reduced FBS-stimulated VSMC numbers by ϳ40% (p Ͻ 0.01) compared with vehicle-treated controls after 72 h (Fig. 2) . Lower concentrations of BAY also reduced cell numbers by ϳ20% (0.001 M BAY, p ϭ 0.196; 0.1 M BAY, p ϭ 0.165) at this time point. Using flow cytometry, a trend for reduced cell numbers in the G 2 /M phase (Ϫ70%; not statistically significant; p ϭ 0.091) in BAY (10 M)-treated cells compared with vehicle controls is apparent with only a slight (nonsignificant) increase in the number of cells in G 0 /G 1 after 24 h (Fig. 3) . No differences were observed between vehicle-and BAY-treated cells in the S phase at this time point. Using the neutral red uptake assay as an indicator of cellular toxicity, no differences be- Figure 4 shows the results of studies examining the effects of BAY on cell migration. Using a scrape injury method, at 18 h postscraping BAY significantly inhibited FBS (10%)-stimulated cell migration at both 0.1 M (50% decrease; p Ͻ 0.01) and 10 M (60% decrease; p Ͻ 0.01) compared with cells in the presence of vehicle alone (Fig. 4D) . Representative photomicrographs are shown for VSMCs immediately after scraping at time 0 (Fig. 4A) , 18 h after scraping in the presence of vehicle (DMSO in DMEM) (Fig. 4B) , and 18 h after scraping in the presence of 10 M BAY (Fig. 4C) . Significant reduction in VSMC migration by BAY was also observed with the scrape injury after 24 h (data not shown); however, by 42 h after scraping, the extent of regrowth was similar for cells in vehicle and BAY treatments at all concentrations (data not shown). In complement, migration of VSMCs was measured using a modified transwell migration system with PDGF as a chemoattractant. After 6 h in the presence of PDGF (20 ng/ml), VSMC migration was reduced by ϳ40% (p Ͻ 0.001) compared with vehicle controls (Fig. 4E) .
Regarding signaling events mediated by BAY, in the presence of the broad PDE inhibitor IBMX BAY (10 M) increased cGMP content more than 200-fold (p Ͻ 0.001) within 20 min, which remained elevated through 60 min (ϳ140-fold; p Ͻ 0.001) compared with vehicle controls (Fig. 5) . In the presence of IBMX, no differences were observed in cAMP content between BAY-treated VSMCs (10 M) and vehicle controls at any time point within 60 min (data not shown).
Considering its novelty, initial studies examined the effectiveness and reproducibility of ICW blotting to that of standardized Western blotting. Using ICW and normalizing to ␣-tubulin within each well, VSMCs in the presence of BAY (10 M; 60 min) doubled pVASPSer 157 and tripled pVASPSer 239 compared with vehicle controls (Fig. 6, A and B, respectively) . The same experimental scheme (including ␣-tubulin normalization) was then used with conventional Western blotting, and results show comparable and dose-dependent up-regulation of both pVASPSer 157 and pVASPSer 239 with BAY (Fig. 6C) . Analyses for ␣-tubulin alone also revealed consistent and reproducible expression patterns from ICW and traditional Western blotting (data not shown).
Using site-specific phosphorylation of VASP as a marker for kinase-specific activation, with pVASPSer 157 suggestive of active PKA and pVASPSer 239 indicative of active PKG (Butt et al., 1994; Deguchi et al., 2002; Chen et al., 2004) in the current study BAY (0.1-10 M, 60 min) dose-dependently increased both pVASPSer 157 and pVASPSer 239 (Fig.  6C) . Increases in pVASPSer 157 and pVASPSer 239 by BAY BAY significantly reduced 10% FBS-stimulated VSMC migration after scrape injury after 18 h at both 0.1 M (50%) and 10 M (60%). D, data showing inhibition of VSMC migration by BAY after scrape injury and stimulation by 10% FBS. Percentage of regrowth after injury was calculated after normalizing readouts to time 0 controls. E, migration was measured using the transwell method with PDGF (20 ng/ml) stimulation after 6 h. BAY significantly reduced (ϳ50%) chemotaxis after 6 h compared with vehicle controls. Data are mean Ϯ S.E.M., with n ϭ 3 for both assays, each performed in duplicate. ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001, Student-NewmanKeuls method for multiple comparisons after one-way ANOVA was used. (0.001-10.0 M; 60 min; normalized to ␣-tubulin) were also observed in rat intact carotid arteries ex vivo (data not shown). In separate sets of ICW and traditional Western blotting experiments, VSMCs were treated with BAY, and total VASP (normalized to ␣-tubulin) was quantitated. Figure 6D shows a representative Western blot, and total VASP (VASP Tot ) including both upper (phosphorylated) and lower (unphosphorylated) bands is only marginally increased in response to BAY (10 M; 24 h) compared with vehicle controls; nonetheless, a dose-dependent increase (8-fold at 10 M BAY) in the levels of phosphorylated (not site-specific) VASP (upper band) normalized to VASP Tot (both bands) is clear. Expression of total PKA and total PKG were not different in BAY-treated cells or BAY-treated intact carotid arteries compared with vehicle controls over a range of BAY concentrations and time points (data not shown). The influence of BAY on site-specific phosphorylation of PKA at serine 338 (pPKASer 338 ) a reported indicator of PKA catalytic activity (Yonemoto et al., 1993) , was also evaluated, and results
show a marked increase in pPKASer 338 in BAY-treated cells compared with vehicle controls (data not shown).
Regarding kinase pathways involved in BAY-driven signaling, the PKA inhibitor PKI (Han et al., 2006) and the PKG inhibitor DT-2 (Dey et al., 2005) have been verified when using VASP phosphorylation as the endpoint (Profirovic et al., 2005; Koika et al., 2010) . The PKG inhibitor DT-2 (10 M) did not significantly reduce BAY-stimulated pVASPSer 157 (ϳ20%; p ϭ 0.14) (Fig. 7A) . It is noteworthy that the PKA inhibitor PKI (10 M) further stimulated BAY-induced pVASPSer 157 by ϳ30% (p ϭ 0.03) compared with BAY alone (Fig. 7A) . In comparison, inhibition of PKG by DT-2 completely eliminated BAY-induced stimulation of pVASPSer 239 (Fig. 7B) ; however, surprisingly, again PKI further increased BAY-stimulated pVASPSer 239 by ϳ50% (p ϭ 0.03) compared with effects of BAY alone (Fig. 7B) . Slight increases in both pVASPSer 239 (p ϭ 0.104) and pVASPSer 157 (p ϭ 0.101) were also observed with 5 M PKI compared with the BAY-treated group (data not shown). The inhibition of PKG by DT-2 even at a lower concentration (5 M) almost completely inhibited BAY-stimulated pVASPSer 239 (p ϭ 0.026) but only marginally reduced pVASPSer 157 (p ϭ 0.19) (data not shown). Considering the kinase signaling pathways involved in growth inhibition by BAY, DT-2 (10 M) did not influence the antiproliferative actions of BAY in VSMCs after 72 h, yet PKI (1 M) partially (p ϭ 0.369) restored the effects of BAY toward control numbers (Fig. 8) . These experiments were conducted over 72 h, so a lower dose of PKI (1 M) was used to avoid unwanted influence from prolonged exposure. Regarding migration, coincubation of VSMCs with BAY and DT-2 completely reversed BAY-mediated inhibition of migration (p Ͻ 0.001); conversely, PKI had no effect on the antimigratory effects of BAY (Fig. 9) .
Discussion
During atherogenesis and after vascular intervention, dysfunction of intimal endothelium can occur concomitant with conversion of medial VSMCs to a growth-promoting, embryonic phenotype. Under such conditions endothelial NOS signaling is often perturbed, yet a compensatory mechanism exists in HO-mediated CO generation. We have shown that under inimical conditions, HO/CO-stimulated cGMP has the capacity to elicit growth-retarding effects in VSM (Tulis et al., 2001 ). This study and others (Chiche et al., 1998) have identified bioactivity of the HO/CO/cGMP system to evoke protection against VSM growth through vasodilatory, antiinflammatory, and antimitogenic activities. Further evidence for the salutary impact of HO/CO-mediated signaling on VSM function can be found in studies using the sGC stimulator YC-1 (Tulis et al., 2002; Wu et al., 2004) , which helped validate the antiproliferative influence of this system on VSM growth.
Using the rat injury model, the present study offers the first evidence demonstrating biological activity of BAY in attenuating vessel remodeling. The influence of BAY was observed only on neointimal growth and not on other vascular parameters, arguing against prolonged vasorelaxation or "outward remodeling" induced by BAY. These results corroborate earlier findings using the BAY prototype YC-1 (Tulis et al., 2002) and provide substantive evidence that pharmacologic sGC/cGMP agonism is a viable option in controlling vessel growth.
In the current study VSMC numbers were reduced by BAY, agreeing with our earlier report in A7R5 VSMCs . Using pharmacologic modulation of the respective NOS and HO pathways, the antiproliferative effects of BAY are believed to principally depend on upstream HO/CO signals and are not influenced by the NOS/NO pathway ). In the current study, additional support for antimitogenic action of BAY was evident from flow cytometry in which BAY markedly (Ϫ70%) reduced cells in G 2 /M. This static effect of BAY on VSM cell cycle progression parallels cell count data and provides sound explanation behind our observations that BAY inhibits growth through Cdk suppression and elevation in p21 and p27 ). The G 2 /M checkpoint is tightly regulated in part by the cyclin E/Cdk2 complex, whose activity increases during late G 2 and allows entry of cells into M. Moreover, the Cdk inhibitor p27 inhibits cyclin E/Cdk2 catalysis. Suppression of Cdk2 activity and elevation in p27 by BAY would retard movement of cells into the mitotic phase and reduce overall numbers in G 2 /M, as observed. Furthermore, the Cdk inhibitor p21 is known to inhibit upstream cyclin D/Cdk4 signaling that is responsible for activation of essential E2F-responsive genes, and elevation in p21 by BAY could contribute to BAY-induced cytostasis. Cytotoxicity analysis reveals that BAY operates through pharmacological and not toxicological mechanisms, supporting our earlier observations .
Regarding migration, in the current study PKG inhibition completely reversed the antimigratory effects of BAY. Considering results demonstrating effectiveness with which DT-2 inhibits pVASPSer 239 in addition to PKG, these data provide sound evidence that BAY inhibits the migration of VSMCs through PKG-driven pVASPSer 239 . The central role of VASP proteins in regulating cytoskeletal dynamics, along with recent findings showing that pVASPSer 239 controls remodeling of the actin skeleton during polymerization (Lund et al., 2010) , offer ample evidence for the antimigratory effects of BAY through cGMP/PKG/pVASPSer 239 .
In our earlier study ) BAY doubled . The presence of BAY significantly reduced (40%) PDGF-stimulated migration of VSMCs after 6 h using a transwell assay. The PKG inhibitor DT-2 completely reversed the antimigratory effects of BAY, whereas the PKA inhibitor PKI had no effect. Data are mean Ϯ S.E.M. of three independent experiments performed in duplicate. ‫,ءءء‬ p Ͻ 0.001; ‫,ءء‬ p Ͻ 0.01; Student-Newman-Keuls method for multiple comparisons after one-way ANOVA.
cGMP and cAMP in A7R5 VSMCs. In the present study in primary VSMCs, cGMP stimulation was much more robust after BAY treatment. It is noteworthy that the earlier study used BAY at 0.001 M, whereas the current study used BAY at 10 M. In addition, both of these studies were performed in the presence of the broad phosphodiesterase (PDE) inhibitor IBMX, albeit at different concentrations and for different durations. In addition, differences in susceptibility toward BAY or other agents may be caused by phenotypic differences including sensitivities to exogenous stimuli between commercial and primary cells. It is noteworthy that in this study under identical conditions as those used to stimulate cGMP no further increases in cAMP were observed with BAY. This is rather surprising because cGMP has been shown to inhibit PDE3, which is responsible for cAMP metabolism (Maurice and Haslam, 1990) . Conversely, it was recently shown that BAY can stimulate PDE3 expression in rat pulmonary VSM (Busch et al., 2010 ). In the current study it seems that IBMX is sufficient to maintain adequate basal levels of cAMP in primary VSM, after which further induction by BAY was not observed. Stimulation of cGMP activates numerous downstream kinases that lead to specific phosphorylation cascades, and in VSM the primary effector of cGMP signaling is PKG. Another target of cGMP action in VSM is VASP, which plays key regulatory roles in cytoskeletal dynamics and migration. As mentioned, site-specific VASP phosphorylation can serve as a biomarker for kinase activation, with pVASPSer 157 indicative of PKA activity and pVASPSer 239 a marker for active PKG (Butt et al., 1994; Chen et al., 2004) . However, other studies provide evidence for cross-talk between PKA and PKG and perhaps other kinases in mediating VASP phosphorylation (Smolenski et al., 1998; Chitaley et al., 2004) , suggesting promiscuity in "site-specific" VASP phosphorylation. In the current study, BAY increased both pVASPSer 157 and pVASPSer 239 . These findings differ slightly from that recently reported in a rat model of pulmonary hypertension (Thorsen et al., 2010) whereby BAY induced pVASPSer 239 yet failed to alter pVASPSer 157 ; however, that study was performed in lung homogenates under hypoxia, whereas the current study examined VSM under normoxia; thus, experimental conditions must be considered in cyclic nucleotide studies when using VASP as a "selective" kinase readout.
In the current study, pharmacologic kinase blockade showed that pVASPSer 239 is solely cGMP/PKG-driven because the PKG inhibitor DT-2 completely abolished this response. In comparison, elevation of pVASPSer 157 , thought to be PKA-specific, was observed after BAY treatment albeit in the absence of detectable increases in cAMP. Moreover, the PKA-specific inhibitor PKI failed to reduce BAY-stimulated pVASPSer 157 and instead exaggerated this response. These findings are surprising but may be a further indication of cross-talk between cGMP and cAMP in terms of VASP phosphorylation. These events show that pVASPSer 157 can be elevated in the absence of cAMP and suggests that this phosphorylation site may involve alternate kinases or PKA inhibition stimulates compensatory mechanisms leading to further increases in pVASPSer 157 and pVASPSer 239 . Sequential and possibly allosteric activation of specific phosphorylation sites, with pVASPSer 239 preceding and inducing pVASPSer 157 , is another possibility after BAY stimulation.
To investigate the mechanisms by which BAY contributes to growth suppression, specific kinase blockade was used in conjunction with BAY treatment. Earlier reports correlated increased pVASPSer 157 and pVASPSer 239 with inhibition of proliferation in rat primary VSMCs (Indolfi et al., 1997; Hewer et al., 2011) . In agreement, in the current study BAY increased pVASPSer 157 and pVASPSer 239 and reduced VSMC proliferation. Moreover, in the presence of PKA inhibition, the antiproliferative ability of BAY was partially reversed, supporting a regulatory role for PKA in VSMC proliferation. A schematic showing our proposed antiproliferative and antimigratory actions of BAY in VSM is shown in Fig. 10 .
It is noteworthy that with nonphosphorylatable VASP mutant VSMCs it has been suggested that pVASPSer 157 promotes whereas pVASPSer 239 inhibits proliferation . In separate studies we observed that low seeding densities reduce PKG expression, which may lend bias to studies examining cGMP signaling in VSMCs (Cornwell et al., 1994) . In this study we plated 25,000 cells/well in 48-well plates for a maximum duration of 72 h, much higher densities and for shorter durations than that reported previously . In addition, preliminary data using pharmacologic blockade of sGC show that the action of BAY in primary VSM depends on an activated cyclase. Thrombospondin-1 and amyloid-␤ are increased in disease conditions including atherosclerosis, diabetes, and Alzheimer's disease and both serve as endogenous sGC inhibitors (Miller et al., 2010a,b) . Moreover, the actions of BAY on sGC are more effective under reduced conditions (Jones et al., 2010) , and in the setting of vascular disease or oxidative stress sGC may become oxidized and rendered less responsive to heme-dependent activation (Stasch et al., 2002 jpet.aspetjournals.org must be used when designing cyclase-specific therapies under inimical conditions whereby endogenous cyclase inhibitors may be elevated and/or the enzyme rendered dysfunctional.
In conclusion, these findings support strategies targeting cGMP signaling in the control of VSM growth. In vivo and in vitro evidence is provided for the sGC stimulator BAY 41-2272, which effectively inhibits neointimal growth by reducing VSMC proliferation and migration through cGMP/PKA and cGMP/PKG/pVASPSer 239 signals, respectively. These data provide the initial evidence for BAY 41-2272 as an antigrowth regulator of VSM and offer support for continued study of its therapeutic potential.
